New CIIE exhibitors highlight strategic commitments to China

Japanese company Kaneka Ubiquinol, which made its debut at this year's China International Import Expo held in Shanghai, said the event's effects have made it interested in participating again next year.

Kaneka Ubiquinol is a prominent supplier of raw materials for ubiquinol, which supports cellular energy production and heart health. Many ubiquinol products by the major global consumer health brands that are available on Chinese e-commerce platforms use raw materials from this company.

"At our CIIE booth, we have been engaging with many local Chinese consumer health brands, and they have shown great interest in our products. We certainly look forward to collaborating with Chinese brands, and hope to bring our products to more consumers on the Chinese mainland," said Kazuki Takita, assistant manager of marketing and sales at Kaneka Ubiquinol APAC.

"By participating in the expo, the company has identified China as a core engine to drive its development in the Asia-Pacific," he said, adding that this move also signifies the company's strategic commitment to deepen its presence in China's fast-growing health and wellness sector.

The spillover effects of the CIIE also brought Lundbeck, a Danish pharmaceutical company focusing on neuroscience, to the expo again after participating for the first time last year.

Eptinezumab, an innovative medicine for preventive migraine treatment, was highlighted at the company's CIIE booth last year. The therapy marked a milestone earlier this year when the latest positive results of its Phase III clinical trial further demonstrated its efficacy in the Asian chronic migraine population.

"As a crucial platform for China's high-level opening-up and global cooperation, the CIIE creates opportunities for global companies like Lundbeck to deepen local partnerships," said Zhang Yifan, managing director of Lundbeck China, adding that China is the company's second-largest market.

"We hope to leverage the CIIE's amplifier and spillover effects to drive awareness of both rare diseases and preventive migraine care, to accelerate our global innovations into China, and to expand partnerships with stakeholders within the local brain health ecosystem," he said.